<DOC>
	<DOCNO>NCT01404091</DOCNO>
	<brief_summary>The purpose trial conduct assessment brain nociceptin/orphanin FQ peptide ( NOP ) receptor occupancy ( RO ) healthy subject .</brief_summary>
	<brief_title>A Study Nociceptin/Orphanin FQ Peptide Receptor Occupancy Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Nociceptin</mesh_term>
	<mesh_term>Nocistatin</mesh_term>
	<criteria>Have body mass index 19.0 30.0 kilogram square meter ( kg/m² ) , inclusive , weight less 125.0 kilogram ( kg ) , physical dimension appear small enough fit magnetic resonance imaging ( MRI ) positron emission tomography scanner ( PET ) Must good health , determine medical history , vital sign , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation Have venous arterial access sufficient allow blood sampling Are nonsmoker least 3 month prior Screening , accord self report ( mean zero cigarette smoke ) Have calculate creatinine clearance great ( &gt; ) 70 milliliter per minute ( mL/min ) Screening Are reliable willing make available duration study willing follow study procedure Will give write informed consent participate study abide study restriction Male subject , whose partner willing use appropriate contraception ( condom spermicidal foam/gel/film/cream/suppository ) time first dose 3 month dose Have receive prescribed systemic topical medication within 14 day first dose administration , unless opinion Investigator medication interfere study procedure compromise safety Have use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day first dose administration ( exception vitamin/mineral supplement ) unless opinion Investigator medication interfere study procedure compromise safety Have receive medication , include St. John 's Wort , know chronically alter drug absorption elimination process within 30 day first dose administration unless opinion Investigator medication interfere study procedure compromise safety Currently enrol , complete , discontinue within last 30 day clinical trial involve investigational product concurrently enrol type medical research judge scientifically medically compatible study Have donate lose 50 499 mL whole blood within 30 day , 499 mL whole blood within 56 day precede first dose administration Have significant history drug allergy determine Investigator Have clinically significant allergic disease ( exclude nonactive hay fever ) , know allergy LY2940094 determine Investigator Have semireclined blood pressure pulse rate high 130/90 millimeter mercury ( mmHg ) 100 beat per minute , respectively , low 90/50 mmHg 40 beat per minute , respectively Consume 14 unit alcohol per week significant history alcoholism drug/chemical abuse/dependence determine Investigator ( one unit alcohol equal ½ pint [ 285 mL ] beer lager , one glass [ 125 mL ] wine , 1/6 gill [ 25 mL ] spirit ) Have positive urine drug screen alcohol breath test result indicate substance abuse screen admission treatment period With , history , clinically significant neurological , gastrointestinal , renal , hepatic , cardiovascular , respiratory , metabolic , endocrine , hematological major disorder determine Investigator With , history , psychiatric illness assess Symptom Checklist ( SCL90R ) Have clinically significant illness within 4 week start dose administration determine Investigator Have serum hepatitis ( B C ) , carrier hepatitis B surface antigen hepatitis C antibody , positive result test human immunodeficiency virus ( HIV ) antibody Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk participate study . In addition , subject follow finding exclude : Confirmed Bazett 's correct QT interval ( QTcB ) great ( &gt; ) 450 millisecond ( msec ) Bundle branch block conduction abnormality ( include 2nd 3rd degree atrioventricular block , complete leave bundle branch block , complete right bundle branch block WolffeParkinsonWhite syndrome , define PR interval le ( &lt; ) 110 msec , confirm repeat ECG mild firstdegree AV block Irregular rhythm sinus arrhythmia occasional rare supraventricular ectopic beat History unexplained syncope Family history unexplained syncope sudden death due long QT ( cardiac output ) syndrome T wave configuration adequate quality assess correct QTc interval Have previously complete withdrawn study study investigate LY2940094 Subjects , opinion Investigator , participate study Taking exclude medication discontinue admission clinical research unit ( CRU ) Have personal family history recurrent seizure complicate febrile seizure Have history significant brain condition/trauma Indicates presence suicidal ideation answer `` yes '' either first two question baseline version Columbia Suicide Severity Rating Scale ( CSSRS ) Screening Have contraindication magnetic resonance imaging ( MRI ) , implant embed metal object fragment head body would present risk magnetic resonance imaging ( MRI ) scan procedure , work ferrous metal either vocation hobby ( example , sheet metal worker , welder machinist ) way might lead unknown , indwell metal fragment could cause injury move response placement magnetic field Have exposure ionize radiation research study , combination study tracer , would result cumulative exposure exceeds recommend exposure limit great ( &gt; ) 20 millisieverts ( mSv ) 1 year Suffer claustrophobia would unable tolerate confine space magnetic resonance imaging ( MRI ) positron emission tomography ( PET ) camera evidence claustrophobia screen Without minimum 37 inch ( 112 centimeter [ cm ] ) top head end wrist allow reasonable access wrist take blood sample positron emission tomography ( PET ) scan Have significant history hypersensitivity reaction gelatin capsule . Any condition , opinion investigator , would preclude participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>